Samsung Biologics
207940.KS
#366
Rank
NZ$89.89 B
Marketcap
$1,263
Share price
2.14%
Change (1 day)
39.18%
Change (1 year)

Revenue for Samsung Biologics (207940.KS)

Revenue in 2024 (TTM): NZ$5.14 Billion

According to Samsung Biologics 's latest financial reports the company's current revenue (TTM ) is NZ$5.17 Billion. In 2023 the company made a revenue of NZ$4.43 Billion an increase over the revenue in the year 2022 that were of NZ$3.62 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Samsung Biologics from 2016 to 2024

Annual revenue

Year Revenue Change
2024 (TTM) NZ$5.14 B15.95%
2023 NZ$4.43 B22.51%
2022 NZ$3.62 B83.5%
2021 NZ$1.97 B41.43%
2020 NZ$1.39 B55.94%
2019 NZ$0.89 B23.27%
2018 NZ$0.72 B23.07%
2017 NZ$0.58 B60.48%
2016 NZ$0.36 B